- Home
- CLH vs ITCI Comparison
CLH vs ITCI Comparison
Compare CLH & ITCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLH
- ITCI
- Stock Information
- Founded
- CLH 1980
- ITCI 2002
- Country
- CLH United States
- ITCI United States
- Employees
- CLH N/A
- ITCI N/A
- Industry
- CLH Environmental Services
- ITCI Biotechnology: Pharmaceutical Preparations
- Sector
- CLH Industrials
- ITCI Health Care
- Exchange
- CLH Nasdaq
- ITCI Nasdaq
- Market Cap
- CLH 14.0B
- ITCI 13.5B
- IPO Year
- CLH 1987
- ITCI N/A
- Fundamental
- Price
- CLH $246.34
- ITCI $126.50
- Analyst Decision
- CLH Strong Buy
- ITCI Buy
- Analyst Count
- CLH 8
- ITCI 13
- Target Price
- CLH $266.75
- ITCI $100.31
- AVG Volume (30 Days)
- CLH 335.9K
- ITCI 4.4M
- Earning Date
- CLH 02-19-2025
- ITCI 02-20-2025
- Dividend Yield
- CLH N/A
- ITCI N/A
- EPS Growth
- CLH 15.34
- ITCI N/A
- EPS
- CLH 7.68
- ITCI N/A
- Revenue
- CLH $5,797,005,000.00
- ITCI $613,728,000.00
- Revenue This Year
- CLH $10.09
- ITCI $48.41
- Revenue Next Year
- CLH $6.03
- ITCI $38.26
- P/E Ratio
- CLH $32.11
- ITCI N/A
- Revenue Growth
- CLH 8.37
- ITCI 46.08
- 52 Week Low
- CLH $167.28
- ITCI $62.78
- 52 Week High
- CLH $267.11
- ITCI $128.00
- Technical
- Relative Strength Index (RSI)
- CLH 63.50
- ITCI 85.99
- Support Level
- CLH $227.01
- ITCI $126.16
- Resistance Level
- CLH $231.17
- ITCI $128.00
- Average True Range (ATR)
- CLH 4.60
- ITCI 2.23
- MACD
- CLH 2.35
- ITCI 4.40
- Stochastic Oscillator
- CLH 94.46
- ITCI 96.82
About CLH Clean Harbors Inc.
Clean Harbors Inc is an environmental and industrial services provider. It provides parts cleaning and related environmental services to commercial, industrial, and automotive customers. Its business segments are Environmental Services and Safety-Kleen Sustainability Solutions. The company generates the majority of its revenues from the Environmental Services segment.
About ITCI Intra-Cellular Therapies Inc.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.